SCHEDULE: Sarepta Divests Entire Stake in Arrowhead Pharma

Sarepta Therapeutics and its investment arm have fully divested their holdings in Arrowhead Pharmaceuticals through a private sale and a share redemption.

Summary

• This document is Amendment No. 1 to the Schedule 13D originally filed on February 14, 2025.
• On August 13, 2025, Sarepta Therapeutics Investments, Inc. sold 9,265,312 shares of Arrowhead Pharmaceuticals, Inc. Common Stock at a price of $18.79 per share in a privately negotiated block trade.
• Concurrently with the sale, Arrowhead Pharmaceuticals, Inc. redeemed and acquired 2,660,989 shares of its Common Stock from Sarepta Therapeutics Investments, Inc. at $18.79 per share.
• The redemption satisfied Sarepta's obligation to pay Arrowhead $49,999,983.31 related to the DM1 First Development Milestone Payment, as defined in their Collaboration Agreement.
• As of August 13, 2025, Sarepta Therapeutics, Inc. and Sarepta Therapeutics Investments, Inc. beneficially own 0 shares, representing 0.0% of Arrowhead's Common Stock outstanding, ceasing to be beneficial owners of more than 5%.

Sentiment

Score: 6

Explanation: The filing reports a significant divestment by a major shareholder. While it resolves a milestone payment for Arrowhead, the complete exit by Sarepta could be viewed with mixed sentiment, potentially raising questions about the long-term strategic alignment or future of the collaboration. For Sarepta, it's a monetization event.

Positives

• Sarepta successfully monetized its investment in Arrowhead through a significant block trade, generating approximately $174.1 million from the secondary sale.
• The redemption of shares by Arrowhead settled a milestone payment obligation from Sarepta, effectively a non-cash settlement for Arrowhead valued at approximately $50 million.

Negatives

• Sarepta's complete divestment could be interpreted as a lack of long-term strategic interest in Arrowhead, potentially signaling a shift in their partnership or focus.
• The sale of a large block of shares (totaling 11,926,301 shares) could put downward pressure on Arrowhead's stock price, depending on market absorption.

Risks

• The complete divestment by a significant shareholder like Sarepta could lead to market speculation regarding the future of the collaboration between the two companies, potentially impacting investor confidence in Arrowhead.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding future operations or financial performance of Arrowhead Pharmaceuticals, focusing solely on the divestment of shares by Sarepta Therapeutics.

Industry Context

This transaction reflects a strategic decision by Sarepta Therapeutics to divest its equity stake in Arrowhead Pharmaceuticals. While the filing does not detail the reasons, such divestments can occur due to shifts in strategic partnerships, portfolio rebalancing, or the monetization of successful investments within the biotechnology and pharmaceutical sectors. The settlement of a milestone payment through share redemption is an interesting mechanism, indicating a pre-existing financial relationship and potentially a re-evaluation of the collaboration's structure.

Related Party Transactions

• The redemption of 2,660,989 shares by Arrowhead Pharmaceuticals, Inc. from Sarepta Therapeutics Investments, Inc. at $18.79 per share, satisfying a $49,999,983.31 milestone payment obligation, constitutes a related party transaction given the existing Collaboration Agreement between Sarepta and Arrowhead.

Stakeholder Impact

• Shareholders (Arrowhead): The divestment by Sarepta could lead to increased trading volume and potential short-term price volatility. The settlement of a milestone payment via share redemption could be seen as a non-dilutive way to settle an obligation, but the complete exit of a strategic partner might raise questions.
• Shareholders (Sarepta): The monetization of their investment in Arrowhead provides capital that can be reallocated to other strategic priorities or returned to shareholders.

Key Dates

Recommendation

The filing details a significant divestment by a major shareholder, Sarepta Therapeutics, from Arrowhead Pharmaceuticals. While the transaction resolves a milestone payment for Arrowhead, the complete exit of a strategic partner could introduce uncertainty regarding the future of their collaboration. For investors, this event warrants a 'hold' recommendation to observe market reaction and any further communications from either company regarding their strategic relationship, as the long-term implications of Sarepta's full divestment are not fully clear from this filing alone.

Keywords

Arrowhead Pharmaceuticals, Sarepta Therapeutics, Schedule 13D, Common Stock, Share Sale, Block Trade, Share Redemption, Milestone Payment, Collaboration Agreement, Biotechnology, Pharmaceuticals, Investment Divestment